ADMA Biologics: Bollinger Bands Narrowing and KDJ Death Cross on 15min chart.

According to the 15-minute chart for ADMA Biologics, the Bollinger Bands have narrowed, indicating a decrease in the magnitude of stock price fluctuations. Furthermore, the KDJ Death Cross occurred on September 26, 2025 at 14:30, which suggests that the momentum of the stock price is shifting towards the downside and may continue to decrease.

Adma Biologics (ADMA) has experienced a notable decline in its stock price over the past month, with shares closing at $15.32 on the most recent trading day. This move represented a -2.17% decrease from the previous session, underperforming the S&P 500's daily loss of 0.5% Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

Heading into today, ADMA shares had lost 9.22% over the past month, trailing the Medical sector's loss of 0.7% and the S&P 500's gain of 2.74%. Analysts and investors are closely monitoring the company's upcoming earnings disclosure, which is expected to post an EPS of $0.16, indicating a 6.67% growth compared to the equivalent quarter last year. The consensus estimate for quarterly revenue is $130.1 million, representing an 8.56% increase from the year-ago period Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

ADMA's full-year Zacks Consensus Estimates call for earnings of $0.57 per share and revenue of $506.7 million, signifying year-over-year changes of +16.33% and +18.82%, respectively. The company's current valuation metrics, including its Forward P/E ratio of 27.47, indicate a premium relative to the industry average Forward P/E of 19.43 Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

According to the 15-minute chart for ADMA Biologics, the Bollinger Bands have narrowed, suggesting a decrease in the magnitude of stock price fluctuations. Additionally, the KDJ Death Cross occurred on September 26, 2025, at 14:30, which may indicate a shift in the stock price's momentum towards the downside .

Investors should keep an eye on these developments as they provide insights into the company's performance and future prospects. For the most up-to-date information, consider visiting Zacks Investment Research (zacks.com) Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].